PL168421B1 - Method of obtaining a pharmaceutic composition for treating stomach disorders - Google Patents

Method of obtaining a pharmaceutic composition for treating stomach disorders

Info

Publication number
PL168421B1
PL168421B1 PL91299319A PL29931991A PL168421B1 PL 168421 B1 PL168421 B1 PL 168421B1 PL 91299319 A PL91299319 A PL 91299319A PL 29931991 A PL29931991 A PL 29931991A PL 168421 B1 PL168421 B1 PL 168421B1
Authority
PL
Poland
Prior art keywords
histamine
cimetidine
receptor antagonist
magnesium
gastric
Prior art date
Application number
PL91299319A
Other languages
English (en)
Polish (pl)
Inventor
Adrian F Davis
Mark Coke
John E O'mullane
Original Assignee
Beecham Group Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group Plc filed Critical Beecham Group Plc
Publication of PL168421B1 publication Critical patent/PL168421B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL91299319A 1990-11-27 1991-11-21 Method of obtaining a pharmaceutic composition for treating stomach disorders PL168421B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909025710A GB9025710D0 (en) 1990-11-27 1990-11-27 Novel treatment
PCT/GB1991/002063 WO1992009286A1 (en) 1990-11-27 1991-11-21 Composition containing antihistamine h2 receptor antagonists and bioadhesive material

Publications (1)

Publication Number Publication Date
PL168421B1 true PL168421B1 (en) 1996-02-29

Family

ID=10686017

Family Applications (1)

Application Number Title Priority Date Filing Date
PL91299319A PL168421B1 (en) 1990-11-27 1991-11-21 Method of obtaining a pharmaceutic composition for treating stomach disorders

Country Status (9)

Country Link
EP (1) EP0559812A1 (ja)
JP (1) JPH06502855A (ja)
AU (1) AU659422B2 (ja)
CA (1) CA2096962A1 (ja)
GB (1) GB9025710D0 (ja)
IE (1) IE914091A1 (ja)
PL (1) PL168421B1 (ja)
WO (1) WO1992009286A1 (ja)
ZA (1) ZA919290B (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4139883A1 (de) * 1991-11-29 1993-06-03 Michael Prof Dr Dittgen Verfahren zur herstellung bioadhaesiver arzneimittel
AU7322394A (en) * 1993-07-06 1995-02-06 Mcneil-Ppc, Inc. H2 antagonist-sucralfate-antiflatulent combinations
WO1995010274A1 (en) * 1993-10-14 1995-04-20 F.H. Faulding & Co. Limited Aqueous pharmaceutical composition
GB9407235D0 (en) * 1994-04-12 1994-06-08 Glaxo Group Ltd Pharmaceutical compositions
US5593696A (en) * 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
KR19980703526A (ko) * 1995-04-03 1998-11-05 나가야마오사무 수크랄페이트 함유 제제 조성물
EP0974361A4 (en) * 1996-02-08 2003-05-02 Chugai Pharmaceutical Co Ltd METHOD OF USING AN ANTI-ACID AGENT AND PHARMACEUTICAL PREPARATION CONTAINING THE SAME
WO1999049872A1 (fr) * 1998-04-01 1999-10-07 Chugai Seiyaku Kabushiki Kaisha Medicaments preventifs des gastrites alcooliques
US6319513B1 (en) 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
WO2023218480A1 (en) * 2022-05-09 2023-11-16 Syri Research Private Limited Liquid oral formulation of famotidine or pharmaceutically acceptable salt thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3710462A1 (de) * 1987-03-30 1988-10-13 Heumann Pharma Gmbh & Co Pharmazeutische zubereitung zur behandlung von erkrankungen des magen-darm-traktes
US4975281A (en) * 1989-01-30 1990-12-04 E. R. Squibb & Sons, Inc. Anti-ulcer composition
EP0403048A3 (en) * 1989-06-14 1991-01-30 Warner-Lambert Company Medicated compositions containing sucralfate and processes for their production

Also Published As

Publication number Publication date
ZA919290B (en) 1992-09-30
WO1992009286A1 (en) 1992-06-11
IE914091A1 (en) 1992-06-03
GB9025710D0 (en) 1991-01-09
JPH06502855A (ja) 1994-03-31
EP0559812A1 (en) 1993-09-15
AU659422B2 (en) 1995-05-18
AU8909891A (en) 1992-06-25
CA2096962A1 (en) 1992-05-28

Similar Documents

Publication Publication Date Title
US5629026A (en) Compositions containing histamine-H2-receptor antagonists at low dosage
JPH05112445A (ja) 作用開始を速くし潜在特性を増加させる移送システム
CA2074215C (en) Improved oral dosing formulations of dideoxy purine nucleosides
HU211236A9 (en) Antacide compositions with prolonged gastric residence time
PL168421B1 (en) Method of obtaining a pharmaceutic composition for treating stomach disorders
US6589507B1 (en) Foaming antacid suspension tablets
EP0533770A1 (en) Novel treatment
US9186409B2 (en) Solid pharmaceutical composition for neutralizing stomach acid
AU4082793A (en) Compositions based on histamine h2-receptor antagonists and cationic exchangers complexes
EP0492247A1 (en) Effervescent H2 blocker formulation
RICHARDSON Sucralfate
Washington et al. An investigation into the effect of cimetidine pre‐treatment on raft formation of an anti‐reflux agent
EP0715520B1 (en) Use of a suspension based on sucralphate gel as antacid
KR960011773B1 (ko) 궤양의 예방 및 치료용 의약 조성물
CA1252045A (en) Fluidized magaldrate suspension
Al-Mudhafar et al. ISSN 0975-413X CODEN (USA): PCHHAX
CN1140996A (zh) 雷尼替丁和碳酸钙药物复合品
WO1996002262A2 (en) Pharmaceutical compositions for the treatment of gastrointestinal distress comprising h2 receptor antagonists and antacids
JPS6287515A (ja) 細胞保護特性を有する外因的酸性化制酸剤組成物
KR19990049931A (ko) 의약 조성물